COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 25 of 74 for:    ORLISTAT

Survey on the Pharmacy Follow-up of Alli Purchasers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01387243
Recruitment Status : Completed
First Posted : July 4, 2011
Last Update Posted : October 29, 2012
Information provided by (Responsible Party):

Brief Summary:
To assess the feasibility and acceptability of genuine pharmacy follow up of people wishing to lose weight.

Condition or disease Intervention/treatment
Overweight Drug: Orlistat

Layout table for study information
Study Type : Observational
Actual Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Survey on the Pharmacy Follow up of Alli Purchasers
Study Start Date : January 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Orlistat

Group/Cohort Intervention/treatment
60 mg Orlistat
Purchased by consumer
Drug: Orlistat
60 mg

Primary Outcome Measures :
  1. Change in Physical activity [ Time Frame: baseline to 1 year ]

Secondary Outcome Measures :
  1. Change in dietary behavior [ Time Frame: baseline to 1 year ]
  2. Evaluation of care pathway (e.g., consultation with doctors, use of nutritional information) [ Time Frame: baseline to 1 year ]
  3. Satisfaction with management (i.e., results on weight and treatment comfort) [ Time Frame: baseline to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Consumers purchasing orlistat in a pharmacy setting

Inclusion Criteria:

  • Individuals who have been recognized as being eligible for treatment, who have agreed to pharmacy follow up, and have given their informed consent to take part in the survey.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01387243

Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT01387243    
Other Study ID Numbers: W5350856
First Posted: July 4, 2011    Key Record Dates
Last Update Posted: October 29, 2012
Last Verified: October 2012
Keywords provided by GlaxoSmithKline:
behavior modification
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Signs and Symptoms
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Obesity Agents
Lipid Regulating Agents